Belite Bio (NASDAQ:BLTE - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.
Belite Bio (NASDAQ:BLTE - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02). On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Belite Bio Trading Up 0.2 %
Shares of BLTE stock traded up $0.10 on Friday, reaching $61.03. 13,005 shares of the company's stock were exchanged, compared to its average volume of 50,104. The company's fifty day simple moving average is $61.90 and its 200 day simple moving average is $63.18. Belite Bio has a 52 week low of $40.00 and a 52 week high of $86.53. The stock has a market capitalization of $1.94 billion, a PE ratio of -54.98 and a beta of -1.48.
Analyst Ratings Changes
BLTE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Belite Bio in a research note on Tuesday, March 18th. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Belite Bio in a research note on Tuesday, March 18th. Finally, Benchmark reiterated a "buy" rating and issued a $80.00 price target on shares of Belite Bio in a report on Wednesday, March 26th.
Get Our Latest Stock Report on Belite Bio
Belite Bio Company Profile
(
Get Free Report)
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Featured Articles
Before you consider Belite Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.
While Belite Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
